Inovio Pharmaceuticals, Inc. Stock News

PLYMOUTH MEETING, Pa. , Dec. 13, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock and accompanying warra...

PLYMOUTH MEETING, Pa. , Dec. 12, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of i...

Data from a retrospective trial evaluating the longer-term benefit of INO-3107 to patients with Recurrent Respiratory Papillomatosis (RRP) involved in a Phase 1/2 trial showed the number of patients who met the criteria for a Complete Response (CR) increased to 50% by the end of year 2 and to 54% in year 3, compared to 28% by the end of the initial 52-week trial 95% of patients in the retrospec...

PLYMOUTH MEETING, Pa. , Nov. 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q3 2024 Earnings Call Transcript November 14, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of IR Jacqui Shea - President and CEO Mike Sumner - CMO Steve Egge - CCO Peter Kies - CFO Matthew Morrow - VP of Translational Sciences Conference Call Participants Jay Olson - Oppenheimer Roy Buchanan - Citizens JMP Sudan Loganathan - Stephens Lian...

New immunology data for INO-3107 supporting proposed mechanism of action presented at several recent conferences  Data showed ability of INO-3107 to induce an antigen-specific cytotoxic T cell response against HPV-6 and HPV-11 and drive recruitment of T cells into airway tissues and papilloma Data showed INO-3107 induced expansion of new clonal T cells that infiltrate airway tissues and corresp...

New immunology data shows INO-3107 induced an expansion of new clonal T cells in blood that were not detectable prior to treatment New clonal T cells in the blood travelled to papilloma and airway tissues and generated an inflammatory and anti-viral response consistent with a reduced need for surgeries for patients with recurrent respiratory papillomatosis (RRP) caused by HPV-6 and HPV-11 Data ...

PLYMOUTH MEETING, Pa. , Nov. 6, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences: 36th International Papillomavirus Conference (Edinburgh, UK; November 12...